Diagnostic Testing For STD’s Market By Type (Syphilis Testing, Gonorrhea Testing, Chlamydia Testing, Herpes Simplex Virus Testing, Human Immunodeficiency Virus Testing, Human Papilloma Virus Testing, Others), By Location (Laboratory Testing, Point Of Care Testing) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The STD diagnostic testing market is expected to reach US$ 42,329.1 million by 2026, up from US$ 19,716.9 million in 2017 and growing at an 8.9% compound annual growth rate (CAGR) from 2018 to 2026. As per the latest research cited by the World Health Organization (WHO), more than 1 million people get infected with a sexually transmitted disease throughout the world every day. Sexually transmitted diseases are most commonly transmitted through sexual contact, but they can also be transmitted through non-sexual means such as blood transfusion. Chlamydia, hepatitis B, gonorrhea, and syphilis have been reported to be transmitted from mother to child during pregnancy and childbirth.

Market Synopsis

The rising preference for multiple sex partners is causing a surge in chlamydia and syphilis infection.

Sexually transmitted diseases are spread by vectors such as bacteria and viruses. The bacterial STIs consist of chlamydia, syphilis, and gonorrhea, whereas the viral STIs consist of herpes simplex virus infection, human immunodeficiency virus infection, and human papillomavirus infection. In the present scenario, chlamydia and syphilis testing are leading the type segment on account of factors such as rising preference for multiple sex partners and increasing sexual contact with the oral and anal regions. Human immunodeficiency virus infection testing will record impressive growth on account of the availability of effective and sensitive molecular diagnostics kits for ELISA and PCR techniques. Proactive government initiatives and rising public health awareness are resulting in early screening for HIV infection.

Enhanced government funding and the availability of a skilled workforce will propel the laboratory testing market's growth.

Laboratory testing is currently dominating the location segment for diagnostic testing in the sexually transmitted diseases market. The key parameters responsible for the market's growth are the enhanced funding received from government healthcare agencies and the availability of a skilled workforce. The rise in per capita income has led to rapid growth in the establishment of private diagnostic laboratories and centers. Point-of-care testing is set to register excellent growth on account of technological advancement in molecular diagnostic kits with pragmatic features such as portability, ease of operation, and quick turnaround time related to diagnosis.

In North America, the rising prevalence of sexually transmitted diseases will drive market growth.

North America is currently leading the regional segment for diagnostic testing in the sexually transmitted disease market. The rising prevalence of sexually transmitted diseases is one of the major factors contributing to North America's dominance. According to the latest statistics provided by the Centers for Disease Control and Prevention (CDC) in 2017, approximately 2.3 million people in the United States were reported to be suffering from gonorrhea, chlamydia, and syphilis. The existence of well-developed healthcare infrastructure with affordable reimbursement scenarios also drives the market growth in North America. The European Medical Agency (EMA) is closely monitoring the spread of sexually transmitted diseases across European Union countries. Following the influx of refugees from the Levant region, the reported number of cases of HIV and HPV infections has skyrocketed. Strict regulatory standards are being implemented, and increased government funding has been announced to combat the spread of sexually transmitted diseases throughout Europe. Asia Pacific will witness magnificent growth during the forecast period on account of rising public health awareness related to sexually transmitted diseases and arduous campaigning by governmental and non-governmental agencies to promote social awareness and free medication for treating STDs.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Market estimation and compounded annual growth rate are covered in the scope of the report for the diagnostic testing market for STDs. The market is segmented by type, location, and region.

Archrivals competing in the diagnostic testing market for STDs are Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., bioMerieux, Danaher Corporation, Diasorin S.p.A., F. Hoffmann-La-Roche Ltd., Hologic, Inc., MedMira, Inc., Qiagen, Inc., and Siemens Healthcare AG.

Key questions are answered in this report.

• How is the market assessment determined by applying inorganic and organic market growth strategies?
• What will be the CAGR and the report's diagnostic testing market for STDs?
• How is the competitive landscape mapped, and what significance does it have in understanding the competition prevalent in the market?
• What is the disease etiology of sexually transmitted diseases?
• Which is the leading and fastest-growing type of segment in the diagnostic testing market for STDs?
• Which is the leading and fastest-growing location segment in the diagnostic testing market for STDs?
• Which is the leading and fastest-growing regional segment in the diagnostic testing market for STDs?

Frequently Asked Questions: